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Abstract
Background: Mesenchymal stromal cells (MSCs) are multipotent progenitor cells used in several cell therapies.
MSCs are characterized by the expression of CD73, CD90, and CD105 cell markers, and the absence of CD34, CD45,
CD11a, CD19, and HLA-DR cell markers. CD90 is a glycoprotein present in the MSC membranes and also in adult
cells and cancer stem cells. The role of CD90 in MSCs remains unknown. Here, we sought to analyse the role that
CD90 plays in the characteristic properties of in vitro expanded human MSCs.
Methods: We investigated the function of CD90 with regard to morphology, proliferation rate, suppression of T-cell
proliferation, and osteogenic/adipogenic differentiation of MSCs by reducing the expression of this marker using
CD90-target small hairpin RNA lentiviral vectors.
Results: The present study shows that a reduction in CD90 expression enhances the osteogenic and adipogenic
differentiation of MSCs in vitro and, unexpectedly, causes a decrease in CD44 and CD166 expression.
Conclusion: Our study suggests that CD90 controls the differentiation of MSCs by acting as an obstacle in the
pathway of differentiation commitment. This may be overcome in the presence of the correct differentiation
stimuli, supporting the idea that CD90 level manipulation may lead to more efficient differentiation rates in vitro.
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Background
Mesenchymal stromal cells (MSCs) are multipotent pro-
genitor cells identified by their plastic-adherence when
maintained under standard culture conditions, self-
renewability, and differentiation into several mesodermal
lineages [1–3]. MSCs are classically able to differentiate
into osteoblasts, adipocytes, and chondroblasts in vitro
[4]. Since their initial description as colony-forming cell
units present in the bone marrow [5], MSCs have been
isolated from many tissue sources such as placenta [6],
dental pulp [7], tendons [8], scalp tissue [9], adipose tissue
[10], umbilical cord blood [11], umbilical cord perivascular
cells [12], umbilical cord Wharton’s jelly [13], synovial
membrane [2], amniotic fluid [14], and breast milk [15].
Due to their relatively easy isolation, multi-differentiation
potential, low antigenicity, and good proliferation/expan-
sion in cell culture, MSCs are considered ideal candidates
for cell-based regenerative therapies [16]. Based on the
minimal criteria established by the International Society
for Cellular Therapy (ISCT), human MSCs are identified
by a combination of high CD105, CD73, and CD90 ex-
pression, and very low/no CD34, CD45, CD11a, CD19,
and HLA-DR expression [4, 17]. Currently, there is no
unique cell marker capable of solely isolating and defining
MSCs. The observation that only a subpopulation of
plastic-adherence isolated MSCs show multipotency [18]
has led to a search for an ideal and definitive single MSC
marker that would not only be specific to MSC, but would
allow direct correlation with stemness [19].
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Although CD90 and STRO-1 are broadly used to iden-
tify MSCs, neither of them is specific to MSCs [20–22].
STRO-1 is only expressed in a low percentage of MSCs.
Some authors also discuss the absence of this marker in
MSCs from all tissue sources [12, 19, 23], and it remains
unclear, in the current literature, whether STRO-1 expres-
sion correlates to MSC stemness. On the other hand,
CD90 is highly expressed in all MSCs, irrespective of the
source, and it is a good marker for CFU-F enrichment
[24]. High CD90 expression has also been related to the
undifferentiated status of MSCs, since a decrease in CD90
level can be correlated with the temporal lineage commit-
ment in vitro [25].
CD90, or Thy-1, is a 25–37 KDa glycosylphosphatidyli-
nositol (GPI)-anchored glycoprotein [26]. CD90 was first
detected in mice T cells [27] and later found to be
expressed in thymocytes, T cells, neurons, hematopoietic
stem cells, cancer stem cells, endothelial cells, and fibro-
blasts [28]. Although it has been shown that CD90 is con-
served among different species, its function seems to vary
according to cell type [29]. CD90 has been reported to
participate in T-cell activation [30], neuritis outgrowth
modulation [31], vesicular release of neurotransmitter at
the synapse [32], astrocyte adhesion [33], apoptosis in car-
cinoma cells [34], tumour suppression [35–37], wound
healing [38], fibrosis [39, 40], and fibrogenesis [41]. Fur-
thermore, it regulates fibroblast focal adhesion, cytoskel-
eton organization, and cell migration [42]. In mouse
models, activation of CD90 expression can be observed in
inflammation, wound healing, and tumour development
[43]. Recent studies suggest that CD90 has a role in onco-
genesis, and it has also been proposed as a marker for can-
cer stem cells (CSCs) in various malignancies [44–51].
Despite an increasing number of studies suggesting
CD90 participation in MSC self-renewal and differenti-
ation [52], its function in MSC biology remains un-
known. The unveiling of the function of CD90 in MSCs
may further facilitate the in vitro manipulation of MSCs
and consequently MSC-based therapies for regenerative
medicine. In this study, we investigated the function of
CD90 in MSC biology. To achieve this objective, we ana-
lysed the effect of CD90 knockdown on proliferation,
morphology, and differentiation of human MSCs.
Methods
Subjects and cell culture
The cells were obtained with the approval of the Ethics
Committee of the Faculty of Health Sciences at the Uni-
versity of Brasilia (Brazil) and University of São Paulo
(Brazil). MSCs were isolated from healthy human tissues
and cultured as previously reported. In the present
study, we obtained MSCs from three different tissue
sources: dental pulp [7] (three donors), adipose tissue
[10] (two donors), and amniotic fluid [14] (two donors).
After isolation, cells were cryopreserved and stored in li-
quid nitrogen. For the assays we used cells that were
stored for no longer than 1 year. Briefly, cells were
thawed and expanded in a regular medium of Dulbecco’s
modified Eagle’s medium (DMEM-LG; Sigma Chemical),
supplemented with 10 % fetal bovine serum (FBS;
Gibco), 100 units/ml penicillin, 100 mg/ml streptomycin
(Gibco), and 10 μl/ml L-glutamine (Gibco) at 37 °C, 5 %
CO2 [1]. The medium was changed every 48 h.
Lentiviral transduction for CD90 depletion
For lentiviral transduction, MSC isolates (a total of seven
samples at cell passage 2) were cultured in a 75-cm2
flask in medium containing 10 % FBS (Gibco), 100
units/ml penicillin, 100 mg/ml streptomycin (Gibco),
10 μl/ml L-glutamin (Gibco) at 37 °C, 5 % CO2. When
cells reached a confluence of 60 %, transduction was
performed in the presence of 8 μg/ml Polybrene (Sigma-
Aldrich) according to the manufacturer’s instructions
(Santa Cruz Biotechnology). CD90 small hairpin
(sh)RNA-expressing lentivirus (shRNA CD90) or non-
targeting shRNA-expressing scramble sequences of RNA
(shRNA control) were then added to the cells at a multi-
plicity of infection (MOI) of 10. The medium was chan-
ged after 24 h. Three days after transduction, stable
clones of MSCs expressing CD90-shRNA (shRNA CD90
MSC) and control shRNA (shRNA control MSC) were
selected using 5 μg/ml Puromycin (Sigma-Aldrich) for
10 days. The medium was changed every 48 h.
Real-time quantitative PCR
Total RNA was extracted from MSCs using Illustra
RNAspin Mini (GE Healthcare), according to the
manufacturer's guidelines. cDNA was prepared with
High-Capacity cDNA Reverse Transcription (Applied
Biosystems) and used as templates for polymerase
chain reaction (PCR). The Kit Power Up SYBR Green
Master Mix (Applied Biosystems) was used to quan-
tify CD90 gene expression by quantitative real-time
(qRT)-PCR under conditions recommended by the
manufacturer and using the following primers:
CACCCTCTCCGCACACCT (forward) and CCCCAC-
CATCCCACTACC (reverse). For normalization of the
data, the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) mRNA was used
(forward primer: AGAAGGCTGGGGCTCATTTG; re-
verse primer: AGGGGCCATCCACAGTCTTC). qRT-
PCR was performed with the StepOne Plus Real-Time
PCR System. A standard curve was generated for
each primer pair, and genes of interest were assigned
a relative expression value interpolated from the
standard curve using the threshold cycle. All expres-
sion values were normalized against GAPDH. All am-
plifications were done in triplicate.
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Magnetic separation of the MSCs for negative selection of
CD90
Cell purification was performed according to the manu-
facturer’s instructions (MiltenyiBiotec). To isolate the
CD90-negative MSC population, shRNA CD90 MSCs
were incubated with anti-CD90-coupled magnetic beads
(MiltenyiBiotec, Germany) for 15 min at 4 °C, rinsed, and
placed in a column. The negative fraction (CD90-negative
MSCs) was collected, and cell purity checked by flow cy-
tometry (FACSVERSE-BD Biosciences, San Jose, CA,
USA) and FlowJo analysis software (TreeStar, Ashland,
OR, USA).
Flow-cytometric analysis
Commercially available monoclonal antibodies were used
for MSC immunophenotyping following the manufac-
turer’s instructions. Subcultures at passage 3 were used for
the flow-cytometric analysis. MSCs were lifted using Try-
pLE (Invitrogen, Carlsbad, CA, USA) and centrifuged for
5 min at 1000 rpm. The supernatant was discarded by as-
piration and the cells incubated for 30 min in a dark envir-
onment in a flow cytometry buffer (phosphate-buffered
saline (PBS), 2 % FBS) containing monoclonal antibodies
against cell surface molecules and their respective isotype
controls. The following antibodies were used: CD14-FITC;
CD29-PE; CD31-PE; CD34-PE; CD44-PE; CD73-PE;
CD90-APC; CD90-FITC; CD106-FITC; CD166-PE and
CD166-PerPC-Cy5.5; CD45-PerCP-Cy5.5; HLA-DR-
PerCP-Cy5.5 (Biosciences); and CD105-PE (clone 8E11;
Chemicon, Temecula, CA, USA). Mouse IgG1-FITC,
IgG1-PE, IgG1 PerCP-Cy5.5, IgG1-APC (Biosciences), and
IgG2A-FITC (AbDSerotec, UK) were used as isotype con-
trols. Cells were analysed using a fluorescence-activated
cell sorter (CyFlowSpace-Partec, Germany; FACSVERSE-
BD or FACSARIA-BD, both from BD Biosciences) and the
data analysed using FlowJo analysis software (TreeStar).
MSC morphology analysis
Transduced and non-transduced MSCs at passage 3 were
placed, in triplicate, in 24-well culture plates (5 × 104 cells/
well). After cell concentration reached a confluence of
70 %, media were removed and the cells were washed with
PBS and fixed with a 4 % paraformaldehyde solution for
15 min at room temperature. Cells were then washed with
PBS, stained with Kit Instant Prov (NewProv, Brazil) and
rewashed with PBS. Cell morphology (shape and size) was
then analysed under an Axiovert inverted microscope
(Zeiss, Germany) and EVOS FL cell imaging system (Life
Technologies, Eugene, OR, USA).
Growth assay
For the assessment of growth characteristics, MSCs (1 ×
105 cells, at passage 3 after transduction, passage 5 after
isolation) were seeded in 75-cm2 culture flasks in MSC
culture medium. Every 48 h, three replicate flasks were
trypsinised and viable cells counted with a haemocytom-
eter. MSC viability was evaluated by Trypan blue exclu-
sion assay.
Lymphocyte proliferation assay
Peripheral blood mononuclear cells were isolated from
peripheral blood and separated using the standard
method with Ficoll-Paque PLUS (Amersham Biosci-
ences, Uppsala, Sweden). The mononuclear cells were
washed twice with PBS buffer. Cells were then counted
in an automated cell counter (2.0 Scepter, Millipore), re-
suspended to a final concentration of 104 cells/ml and
labelled with CFSE (Sigma-Aldrich). The CFSE was ad-
justed to a final concentration of 5 μM and incubated
for 10 min at 37 °C. The reaction was stopped by adding
RPMI with 10 % FBS. In immediate succession, 2 × 104
lymphocytes were cultured with or without 5 × 104
MSCs previously adhered to the bottom of a 24-well
plate in a total volume of 1 ml per well of RPMI with
10 % FBS medium. To evaluate the lymphocyte prolifer-
ation rate in the presence of MSCs, cell suspensions
were activated with a phytohaemagglutinin (PHA;
Sigma, USA) stimulus at a final concentration of 1 μg/
ml in cell culture and maintained at 37 °C with 5 % CO2
for 5 days for subsequent assessment by flow cytometry
(CyFlowSpace-Partec, Germany) and the FlowJo analysis
software (TreeStar) [53]. Suspension cells were stained
with CD8-PE antibody (Biosciences), and lymphocyte
proliferation was measured according to CFSE staining
on gated population.
In vitro differentiation assays
To evaluate the differentiation potential of MSCs, cells
were subjected to in vitro osteogenic and adipogenic dif-
ferentiation according to the established protocols [1].
Transduced and non-transduced MSCs at passage 4
(passage 2 after transduction) were seeded in 24-well
plates at a density of 5 × 104 cells/well. When a conflu-
ence of 80 % was achieved, the regular medium was re-
placed with an induction medium, which was refreshed
every 72 h for 21 days. Cells cultured in regular medium
were used as controls.
Osteogenic differentiation
MSCs were placed in 24-well plates at a density of 5 ×
104cells/cm2 the previous day and then treated with osteo-
genic supplements as previously described [1] for 21 days.
The osteogenic medium contained 100 nM dexametha-
sone (Sigma-Aldrich), 10 mM 2-β-glycero-phosphate
(Sigma-Aldrich), and 50 μM of L-ascorbic acid-2-
phosphate (Sigma-Aldrich). Osteogenic differentiation was
evaluated by alkaline phosphatase (ALP) activity, calcium
concentration determination, and colorimetric Alizarin red
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staining. Mineralized matrix formation after osteogenic dif-
ferentiation was detected as previously described [1]. Sam-
ples were fixed with 4 % paraformaldehyde for 15 min,
rinsed in PBS, and dyed for 20 min with 40 mM Alizarin
Red solution (Sigma-Aldrich) at pH 4.2 and room
temperature. Cells were washed five times with distilled
water, followed by an immediate 15-min rinse with PBS to
reduce non-specific dying. The resulting samples were
analysed and photographed under an Axiovert inverted
microscope (Zeiss, Germany). To determine alizarin red
concentration, the samples were exposed to 10 mM so-
dium phosphate containing 10 % cetylpyridinium chloride
(Sigma-Aldrich) at pH of 7.0 for 15 min at room
temperature. The Alizarin Red concentration was deter-
mined by measuring absorption at 562 nm using a spectro-
photometer (SpectraMax M2, Molecular Devices, USA).
Results were expressed as a percentage of the respective
controls, which were normalized to 100 % [54]. Lysate al-
kaline phosphatase activity was measured spectrophoto-
metrically using a Sigmafast p-nitrophenyl phosphate kit
(Sigma-Aldrich). For ALP assays, cells were washed with
PBS and lysed in 0.05 % Triton X-100 through three cycles
of freezing and thawing. A lysate aliquot was incubated
with p-nitrophenyl phosphate substrate (p-NF) at 37 °C for
30 min. The reactions were stopped by adding 5 μl 1 N
NaOH and absorbance measured at 405 nm using a spec-
trophotometer (SpectraMax M2, Molecular Devices) [55].
A pattern curve of p-NF was established in order to deter-
mine the enzymatic activity. Samples were normalized and
total protein quantification determined by the Lowry
method [56].
The quantitative levels of calcium in cell samples were
determined for both osteogenic differentiation-induced and
non-induced cells. Supernatant calcium concentration was
determined by colorimetry using the ortho-cresolphthalein
complexone (o-CPC) method [57]. Cells were trypsinised,
resuspended in PBS, and then reacted with a calcium re-
agent containing 0.69 mol/l ethanolamine buffer, 0.2 % so-
dium azide, 0.338 mmol/l 0-cresolphthalein complexone,
and 78 mmol/l 8-hydroxynquinoline-13. Cell reactions
were read by a spectrophotometer (Advia2400, Siemens).
Adipogenic differentiation
For adipogenic induction, cells were seeded in 24-well
plates at a density of 5 × 104 cells/cm2. When the cells
reached confluence, they were treated with an adipo-
genic induction medium containing 5 mg/ml insulin,
5 mmol indomethacin, 1 mmol dexamethasone, and
0.5 mmol/l isobutyl-1-methylxanthine (all from Sigma-
Aldrich) in regular medium. Adipocyte formation was
monitored by the appearance of lipid droplets under a
microscope. After the induction period, cytochemical
analysis of the differentiated and control cells was per-
formed by conventional optical microscopy. The cells
were fixed in 4 % formaldehyde for 15 min, rinsed in
PBS, and dyed for 30 min with 0.5 % Oil Red O (Sigma-
Aldrich) in ethanol. Cells were subsequently washed five
times with distilled water to remove any excess dye.
Quantification of lipid accumulation was achieved by
extracting Oil Red-O from stained cells with isopropanol
and measuring the OD of the extract at 510 nm using a
Spectramax M2 spectrophotometer (Molecular Devices)
[58].
Statistical analysis
Statistical analysis was performed using the software
GraphPad™ (San Diego, CA, USA). Quantitative data
were expressed as mean ± standard deviations (SD) and
statistical analyses of variance (ANOVA). Multiple com-
parisons were performed with Tukey's HSD test when
appropriate. Findings with p < 0.05 were considered sta-
tistically significant.
Results
MSC isolates and purity
MSCs were obtained from dental pulp (DPSC; three do-
nors), amniotic fluid (AF-MSC; two donors), and adipose
tissue (ADSC; two donors). The success rate of isolating
MSCs from all tissues was 100 %. Cells from all three
sources (a total of seven isolates) contained a high num-
ber of adherent MSC-like cells which proliferated rapidly
in number. Analysis of positive and negative characteris-
tics for human MSC surface antigens by flow cytometry
for cultured MSCs showed a high purity (≥97 %) of the
cells (Additional file 1: Table S1).
Analysis of the CD90 downregulated expression effect in
MSCs
To initiate our study, we reduced CD90 expression in
MSCs (DPSC, AF-MSC, and ADSC) by transducing
commercially available lentiviruses expressing three
CD90 shRNAs. After transduction, the MSC lines stably
expressing shRNA CD90 and shRNA control were estab-
lished by antibiotic selection. To confirm CD90 reduc-
tion, unmodified/non-transduced MSCs, shRNA CD90
MSCs, and shRNA control MSCs were analysed by flow
cytometry (Fig. 1a and b) and qRT- PCR (Fig. 1c). Non-
transduced MSCs and shRNA control MSCs showed the
same level of CD90 expression (mean 98 %), whereas
shRNA CD90 MSCs presented reduced CD90 expression
(mean 23.9 %) (Fig. 1b). Transduction and establishment
of shRNAs (CD90 and control) expressing MSCs were
performed using samples from all tissues, with similar
levels of reduction in CD90 expression observed in all
samples (Additional file 1: Table S1). qRT- PCR con-
firmed that shRNA CD90 used here effectively reduced
transcript levels of CD90 (Fig. 1c).
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Since CD90 expression was not completely ablated in
shRNA CD90 MSCs, we submitted shRNA CD90 MSC
samples to magnetic-activated cell sorting and collected
the post-separation CD90-negative fraction (subse-
quently termed CD90-negative MSCs). CD90-negative
MSCs were characterized by flow cytometry to verify
purification success. Flow cytometry analysis confirmed
that the CD90-negative MSCs samples expressed lower
levels of CD90 than shRNA CD90 MSCs (Fig. 2).
Morphology and growth kinetics
In our cellular morphology analysis of the cells used in
this study, we observed no differences in the shape and
size of MSCs, shRNA control MSCs, shRNA CD90
MSCs, CD90-negative MSCs, and non-transduced MSCs
(Fig. 3a). The shRNA CD90 MSCs and CD90-negative
MSCs derived from all three sources displayed characteris-
tic MSC/fibroblast-like morphology. We also observed that
shRNA CD90 MSCs and CD90-negative MSCs maintained
their capacity to form colonies for up to 10 passages, sug-
gesting that CD90 is not involved in the maintenance of
MSC cell morphology and colony-forming ability.
In order to assess the role of CD90 in MSC proliferation
rate, cell growth curves for MSCs, shRNA control MSCs,
shRNA CD90 MSCs, CD90-negative MSCs, and non-
transduced MSCs at the same corresponding cell passage
(cell passage 5) were conducted in parallel (Fig. 3b). Ana-
lysis of the area under the curve showed no significant dif-
ference in proliferation rates. The trypan blue exclusion
assay also showed no difference in cell viability.
Lymphocyte proliferation analysis
We also investigated whether CD90 expression in MSCs
would affect the inhibitory effect of MSCs on non-
specific mitogen-stimulated lymphocytes in an in vitro
assay. The assay showed that shRNA CD90 MSCs and
CD90-negative MSCs suppressed peripheral blood
mononuclear cell proliferation to the same extent as
MSCs and shRNA control MSCs and non-transduced
MSCs (Fig. 4a and b), indicating that a reduction in the
expression of CD90 does not affect the characteristic im-
munosuppressive effect of MSCs on lymphocyte prolifer-
ation. Further analysis shows that ablation of CD90 on
MSCs also does not affect the percentage of proliferated
CD8+ T cells (Fig. 4c).
Flow cytometry immunophenotyping
We further analysed the cell expression of the MSC
marker panel. As expected, and as for non-transduced
MSCs, shRNA control MSCs, shRNA CD90 MSCs, and
CD90-negative MSCs were negative for the expression
of the following markers: CD14, CD31, CD34, CD45,
CD106, and HLA-DR, but they were positive for CD29,
CD73, and CD105 (Additional file 1: Table S1 and Add-
itional file 2: Figure S1). Surprisingly, we found a reduc-
tion in the expression of the CD44 and CD166 markers
in shRNA CD90 MSCs, suggesting that the CD90 reduc-
tion is linked to the decrease in CD166 and CD44 ex-
pression (Fig. 5a and b). These reductions were observed
in MSCs from all three sources (Fig. 5a).
Fig. 1 Reduction of CD90 in MSCs. a Non-transduced mesenchymal stromal cells (MSC) and MSCs transduced with lentiviral particles expressing
short hairpin (sh)RNA against CD90 (shRNA CD90 MSC) were analysed by flow cytometry. An accentuated decrease in CD90 expression is observed
in shRNA CD90 MSC (thick line), whereas non-transduced MSCs (slim line) expressed high levels of CD90. The shaded histogram indicates staining
with isotype control antibody. Representative histograms from dental pulp MSCs are shown. b Significant decrease of CD90 median fluorescence
intensity (MFI) on shRNA CD90 MSCs when compared to non-transduced MSCs. (MFI = MFI marker – MFI isotype). Bar graphs represent the average
mean fluorescence intensity as the median ± SD of CD90-FITC on cell lines used in this work; n = 7; ****p < 0.001. c Relative mRNA expression levels of
CD90 in MSC, shRNA control MSC, and shRNA CD90 MSC had consistently low expression of CD90. Data are presented as mean ± SD of experiments
performed in triplicate; *p < 0.05
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CD90 and MSC differentiation
The differentiation potentials of non-transduced MSCs,
shRNA control MSCs, shRNA CD90 MSCs, and CD90-
negative MSCs were analysed in parallel in multilineage
(osteogenic and adipogenic) differentiation assays. MSCs
isolated from dental pulp, amniotic fluid, and adipose tis-
sue were submitted to osteogenic differentiation assays. As
expected, osteogenic induction (OS) resulted in the occur-
rence of a mineralized matrix deposition which was de-
tected 21 days after the initiation of differentiation
Fig. 3 Reduction of CD90 expression does not affect mesenchymal stromal cell (MSC) morphology and proliferation rate. a Representative phase
contrast microscopy images of MSCs derived from dental pulp. All MSCs displayed a spindle-like morphology exhibiting relatively thin processes
extending from the cell bodies. The photographs shown here are representative of all samples analysed (n = 7). b Proliferation curves of non-
transduced MSCs, short hairpin (sh)RNA control MSCs, shRNA CD90 MSCs, and CD90-negative MSCs. Data shown represent the mean ± SD of two
independent experiments performed in triplicate with dental pulp MSCs from two tissue donors; *p < 0.05
Fig. 2 CD90-negative selection of shRNA CD90 MSCs by magnetic-activated cell sorting. Mesenchymal stromal cells (MSCs) expressing short
hairpin (sh)RNA CD90 (shRNA CD90 MSC) were magnetically labelled with CD90 microbeads, and MSC populations negatively selected for CD90
(CD90-negative MSCs). a Histogram superposition: isotype control (shaded histogram grey), non-transduced MSCs (black slim line), shRNA control
MSCs (grey line), shRNA CD90 MSCs (blue line), and CD90-negative MSCs (black thick line).Representative histograms from a dental pulp MSC group
are shown. b Graph showing mean fluorescence intensity (MFI) of CD90 marker (MFI = MFI marker – MFI isotype) on cells; n = 7, independent
experiments with MSCs derived from 7 tissue donors; ****p < 0.001
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induction. The mineralized matrix was assessed by: a) Ali-
zarin Red S Staining (AR); b) determination of calcium
concentration; and c) alkaline phosphatase activity. Ac-
cording to previous data reported by other groups [7,
59, 60], mineral deposition was higher in MSCs isolated
from dental pulp than in those isolated from lipoaspirate
tissue (Fig. 6). The AR staining pattern obtained differs ac-
cording to the level of CD90 expression (Fig. 6). The
shRNA CD90 MSCs showed significantly higher produc-
tion of osteogenic matrices, with the visualization of a
higher concentration of AR dye in the samples, in compari-
son to both non-transduced MSCs and shRNA control
MSCs (Figs. 6 and 7a). Even higher mineralization was ob-
served in CD90-negative MSC samples. The effect of re-
duced CD90 expression on the osteogenic differentiation
of MSCs was also assessed by monitoring alkaline phos-
phatase activity, which demonstrated an enhanced produc-
tion of this enzyme in cells with reduced CD90 expression
(Fig. 7b). The calcium production by shRNA CD90 MSCs
was also higher than in non-transduced MSCs (Fig. 7b).
The calcium concentration could not be adequately mea-
sured in samples originating from lipoaspirate tissue due
the low calcium concentration in all samples.
The adipogenic differentiation capacity of the MSCs
was also analysed using MSCs isolated from dental
pulp, adipose tissue, and amniotic fluid (Fig. 8). All
cell populations showed significant morphological
changes compared to those that were not incubated
in adipogenesis-inducing medium. The cells presented
an oval shape, with lipid vacuoles in the cytoplasm,
and the presence of many lipid droplets as evidenced
by Oil Red staining (Fig. 8a). We observed an in-
crease in the number of adipocyte-like cells in shRNA
CD90 MSCs compared to the shRNA control MSCs,
with an even higher number of adipocyte-like cells in
CD90-negative MSCs. Independent of CD90 expres-
sion, we found that MSCs from adipose tissue pro-
duced higher amounts of lipid droplets when
compared to cells obtained from the amniotic fluid
and dental pulp. The most prominent adipocyte for-
mation, revealed by Oil Red staining, was observed in
CD90-negative MSCs isolated from adipose tissue
(Fig. 8b).
Discussion
The biology of MSCs has been broadly studied [1, 22, 61,
62] because of their therapeutic potential. Therefore, we de-
cided to study the function of CD90, one main immuno-
phenotypical marker of MSCs, in order to better
understand its relationship with MSC morphology, prolifer-
ation, and differentiation. Here, we used MSCs isolated
from three sources (dental pulp, adipose tissue, and amni-
otic fluid) to verify whether the effects caused by CD90 ab-
lation would be source-specific. We used lentivirus-
mediated CD90-shRNAi to stably reduce CD90 expression
and further evaluate its function in MSCs. Here, we gener-
ated MSC lines transduced with lentivirus-carrying small
hairpins (shRNA) targeting CD90. After the establishment
of CD90-shRNA expressing MSCs (in shRNA CD90
MSCs), the reduction of CD90 expression was confirmed
Fig. 4 T-cell proliferation assays. Assays were performed using carboxyfluorescein succinimidyl ester (CFSE)-labelled human peripheral blood
mononuclear cells (PBMC) activated with phytohaemagglutinin and co-cultured with or without human dental pulp mesenchymal stromal cells
(MSC) for 5 days. a Representative histograms from dental pulp MSC cytometry analysis are shown (n = 3). b Histograms showing number of
CFSE-labelled activated cells. c Histograms showing percentage proliferation of CFSE-labelled CD8+ T cells. n = 3; *p < 0.05. sh short hairpin
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in immunophenotypical analysis using flow cytometry
(Fig. 1). We subsequently evaluated the immunophenotypic
profiles of modified MSCs, in addition to CD90. As ex-
pected, we found that these cells expressed the positive
MSC markers CD29, CD73, and CD105, and did not ex-
press the following cell markers: CD14, CD31, CD34,
CD45, CD106, and HLA-DR (Additional file 2: Figure S1).
Surprisingly, we found that a knockdown in CD90 expres-
sion in all CD90-shRNAi MSCs obtained here led to a re-
duction in the CD44 and CD166 expression (Fig. 5).
The role of CD166 in MSCs has not been determined
to date. However, CD44 (hyaluronan receptor) [63] is
expressed by a large number of cells and is involved in
cell adhesion, migration, and homing in MSCs [64–66].
Furthermore, CD44 has been recognized as a stem cell
marker for several types of cancer and is strongly linked
to metastatic spread. It has been shown that the reduc-
tion of CD44 in cancer stem cells caused them to differ-
entiate into non-cancer stem cells [67]. The receptor
CD166 (activated leukocyte cell adhesion molecule,
ALCAM) is a member of the immunoglobulin superfam-
ily of cell adhesion molecules [68, 69] and is present in
undifferentiated MSCs and other cell types [70]. Like
CD44, CD166 has been shown to participate in tumour
invasion [71–73]. A recent study using liver cancer cell
lines relates the close interaction between CD44 and
Fig. 5 Reduction of CD90 expression leads to a reduction in the expression of CD44 and CD166 in mesenchymal stromal cells (MSCs). a MSCs (slim
line) and shRNA CD90 MSCs (thick line) were analysed by flow cytometry to evaluate their expression of CD44 and CD166. The results showed a
significant reduction of CD44 and CD166 expression in shRNA CD90 MSCs from different tissue sources. An isotype control (shaded histogram) was
used to establish the boundary between negative and positive fluorescent regions. Median fluorescence intensities (MFI) of b CD44 and c CD166
markers on MSCs are shown (MFI =MFI marker – MFI isotype); n = 7; *p < 0.05. ADSC adipose tissue mesenchymal stromal cell, AF-MSC amniotic fluid
mesenchymal stromal cell, DPSC dental pulp mesenchymal stromal cell, sh short hairpin
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CD166. The authors showed that a knockdown of
CD166 inhibits the expression of CD44 via the NFkB
pathway [74].
CD90 has also been identified as a candidate marker for
adult stem cells. Few studies have shown a functional asso-
ciation between CD90 and CD44 or CD166 markers. Strik-
ingly, the few data showing association come from cancer
stem cell research: CD90, CD44, and CD166 are notably
considered cancer stem cell markers [44, 70, 71, 75]. Our
results showed that the knockdown of CD90 leads to a de-
crease in CD44 and CD166 expression, which could indi-
cate a shift in the stemness state of MSCs towards a state
more susceptible to differentiation.
CD90 has been linked to the spindle-shape of lung fi-
broblasts. Observing lung fibroblasts sorted on the basis
of CD90 expression, Phipps and co-workers [76] affirmed
that the lung CD90– fibroblast subpopulation showed a
more polygonal shape than the spindle-shaped CD90+ fi-
broblasts. In contrast to these observations, in our study, a
reduction in CD90 expression in shRNA CD90 MSCs and
CD90-negative MSCs did not present altered morphology
or proliferation rate when compared to control cells
(Fig. 3). Here, we also demonstrated that a reduced ex-
pression of CD90 does not affect the immunosuppressive
activity of MSCs on lymphocyte proliferation in vitro
(Fig. 5), a very important therapeutic MSC property.
We carried out assays to investigate the differentiation
of CD90-ablated MSCs into osteogenic and adipogenic
lineages. In our differentiation assays, shRNA CD90
MSCs and CD90-negative MSCs showed a higher rate of
adipogenic differentiation when compared to the con-
trols (Fig. 8). In the same way, an enhanced osteogenic
differentiation was observed in samples of shRNA CD90
MSCs and CD90-negative MSCs. Alizarin Red S staining
showed that CD90-negative MSCs, the CD90 negative
fraction of shRNA CD90 MSCs, accumulated more min-
eralized matrix than shRNA CD90 MSCs (Figs. 6 and 7).
According to our results, the knockdown of CD90 ex-
pression in MSCs facilitates osteogenic and adipogenic
differentiation.
Recently, Woeller and colleagues [77] showed that
CD90 controls adipogenesis. They had previously
Fig. 6 Reduction of CD90 expression stimulates MSC osteogenesis. MSCs, shRNA control MSCs, shRNA CD90 MSCs, and CD90-negative MSCs from
dental pulp (DPSC), amniotic fluid (AF-MSC) and adipose tissue (ADSC) were tested in parallel for their ability to differentiate in vitro into osteogenic
lineages. Calcified deposits were evidenced by Alizarin Red Staining (AR) in cells after 4 weeks of growth in osteogenic induction medium. Calcification
was assessed by gross appearance (a) and light microscopy (b). Data shown are representative of multiple replicates. OS osteogenic induction, sh
short hairpin
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observed that CD90-null mice gain weight at a faster rate,
and that ectopic overexpression of CD90 blocked adipo-
genesis [77]. They also stated that, although pre-adipocyte
fibroblasts expressed CD90, fat adipocytes presented al-
most undetectable CD90 levels. In agreement with this
study, we also observed that a loss of CD90 expression in
MSCs increased the production of adipogenic matrix in
vitro. Based on their study, Woeller and colleagues [77]
suggest that CD90 could be a new therapeutic target for
obesity. However, our results indicate that this differenti-
ation facilitation related to decreased CD90 expression is
not only for adipogenic differentiation, since we observed
the same facilitation for osteogenic differentiation. Our
data indicate that the knockdown of CD90 seems to lower
the stemness guard of MSCs, thereby enabling further dif-
ferentiation when in the presence of the specific stimuli.
The finding that the level of CD90 regulates both
MSC adipogenesis and osteogenesis is very interesting,
because it is well accepted that differentiation stimuli
usually cause an “inverse relationship” between adipo-
genic and osteogenic differentiation [78], although the
molecular pathways that can converge into adipogenesis
and osteogenesis have not been completely elucidated.
Here, we demonstrated that the production of mineral-
ized matrix directly correlates with the level of CD90 ab-
lation: higher in the samples of CD90-negative MSCs
than shRNA CD90 MSCs. It is unclear how CD90 can
affect adipogenesis. However, it has been demonstrated
that CD90 also regulates RhoGTPase activity in fibro-
blasts. Exogenous expression on CD90-non-expressing
fibroblasts results in Rho GTPase activation [42]. CD90
participates in many signalling pathways, and it is be-
coming clear that, although CD90 has been recognized
as a plain cell marker, it is also an important regulator of
MSC signalling [79]. In order to accurately understand
the effects of CD90 on all cis- and trans-signalling
networks that it participates in, significant further stud-
ies are required. Improving our knowledge of these
mechanisms may allow a better understanding of MSC
stemness and differentiation.
An increasing number of studies have shown that
MSCs from different sources display significantly di-
verse properties and characteristics that may impact
on their future therapeutic applications. The capacity
of differentiation may vary according to the cell
source [7, 59, 60]. In agreement with previous reports
[59, 80–82], we observed that cells from the dental
pulp tissue and aminiotic fluid produced a larger
quantity of osteogenic matrix than cells from adipose
tissue (Figs. 6 and 7). Despite the expected variance
in the differentiation potential among MSCs from dif-
ferent tissues [83, 84], we confirm that a reduction in
CD90 expression leads to a more efficient osteogenic
differentiation, irrespective of the source.
CD90 is a GPI-anchored protein expressed in vari-
ous cell types. In general, it appears to influence cell
proliferation, differentiation, migration, and survival.
The functions of CD90 are tissue- and cell-specific
and, in the present work, we found that shRNA-
induced knockdown in human MSCs increases the
Fig. 7 Quantitative evaluation of osteogenesis. a Quantification of Alizarin Red staining by dissolving the dye and subsequent absorption measurement.
b Alkaline phosphatase (ALP) activity in cells cultured in osteogenic medium. ALP activity (mU μmol p-nitrophenol released per min) was normalized for
protein. c Calcium concentration determinations were possible only for DPSC samples and AF-MSC samples. The data are expressed as mean ± SD and are
representative of two independent experiments, each performed in triplicate (DPSC = 2 donors, ADSC = 2 donors, AF-MSC= 2 donors). *p< 0.05; **p< 0.01;
***p< 0.001. ADSC adipose tissue mesenchymal stromal cell, AF-MSC amniotic fluid mesenchymal stromal cell, DPSC dental pulp mesenchymal stromal cell,
MSC mesenchymal stromal cell, sh short hairpin
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differentiation efficiency of these cells. Our group previ-
ously showed that CD90 expression could be used as an
indicator to follow the differentiation commitment degree
of MSCs. Immediately after the induction of differenti-
ation, a progressive decrease in CD90 mRNA level corre-
lates with the degree of differentiation observed [25]. It is
Fig. 8 Reduction of CD90 expression stimulates the adipogenesis of mesenchymal stromal cells (MSCs). MSCs, short hairpin (sh)RNA control MSCs,
shRNA CD90 MSCs, and CD90-negative MSCs were tested for their ability to differentiate into adipogenic lineages. a Representative photomicrograph
images show oil red staining indicative of adipogenic differentiation. MSCs from dental pulp (DPSC), amniotic fluid (AF-MSCs), and lipoaspirate (ADSC)
were cultured in the non-differentiation medium MSCs (control) and adipogenic differentiation medium (AD). The images shown are representative of
two independent experiments. b Oil red dye retained in the lipid vacuoles was measured by determining the optical density (OD) at 510 nm. Data
shown represent the mean ± SD of one experiment performed in triplicate (n = 7). *p < 0.05; **p < 0.01; ***p < 0.001
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important to reiterate that the ablation of CD90 expres-
sion did not result in a spontaneous differentiation. How-
ever, it facilitated MSC differentiation in the presence of
inductors, indicating that CD90 may play an important
role in maintaining the undifferentiated state of MSCs,
perhaps by acting as an obstacle to be overcome during
the early steps of cellular differentiation commitment.
Conclusions
Taken together, the current data indicate that the abla-
tion of CD90 in MSCs represents a promising alternative
strategy and an efficient approach to increase MSC dif-
ferentiation efficiency in vitro; it may, therefore, be used
in the future to improve MSC differentiation yields in
cellular therapy. Further studies are needed to evaluate
whether this approach facilitates all the in vitro differen-
tiation protocols established for MSCs, and how the ab-
lation of CD90 affects migration/homing and the
therapeutic potential of those cells in in vivo MSC ther-
apy models. Our results showed that the knockdown of
CD90 leads to a decrease in CD44 and CD166 expres-
sion, which could indicate a shift in the stemness state
of MSCs towards a state that is more susceptible to
differentiation.
Additional files
Additional file 1: Table S1. Surface protein expression of transduced
and non-transduced MSCs originated from dental pulp (DPSC) (n = 3),
amniotic fluid (AF-MSCs) (n = 2), and lipoaspirate (ADSC) (n = 2) were
analysed by flow cytometry. Data shown represent the mean MFI ± SD
obtained in cytometry analysis performed in duplicate. (TIF 177 kb)
Additional file 2: Figure S1. Representative flow cytometry data to
characterise transduced and non-transduced MSC groups studied in this
work. One representative immunophenotypic analysis of groups obtained
from the same dental pulp tissue is shown. Unstained MSC (grey shaded
histogram), MSC (grey line), shRNA control MSCs (black slim line), and
shRNA CD90 MSCs (black thick lines) were harvested and labelled with Ab
against CD90, CD44, CD166, CD73, CD29, CD14, CD45, CD31, CD34,
CD106, and HLA-DR as indicated. FACS analysis demonstrated that MSCs
and shRNA CD90 MSCs were negative for CD14, CD45, CD31, CD106,
HLA-DR, and CD34, and were positive for CD105, CD73, and CD29. MSCs
were positive for CD90, CD44, and CD166, whereas shRNA CD90 MSCs
showed a reduction in CD90, CD44, and CD166 expression. (TIF 8631 kb)
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